CIS
KITE

Capital International Sarl’s Kite Pharma, Inc. KITE Stock Holding History

Capital International Sarl’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,000
Closed -$1.87M – 150
2017
Q2 		$1.87M Hold
18,000
– – 0.16% 104
2017
Q1 		$1.41M Sell
18,000
-1,100
-6% -$68K 0.12% 114
2016
Q4 		$856K Hold
19,100
– – 0.08% 129
2016
Q3 		$1.07M Buy
+19,100
New +$1.06M 0.09% 131

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Sarl's KITE Position: Q3 2017 in Review

Capital International Sarl sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 18,000 shares — an estimated $1.87M sold.

Capital International Sarl first reported a position in KITE in Q3 2016 and held it in 4 quarters. The position peaked at $1.87M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Capital International Sarl reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Capital International Sarl sold 18,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $1.87M.
  • Capital International Sarl first reported a position in Kite Pharma, Inc. in Q3 2016 and held it in 4 quarters.
  • Capital International Sarl's Kite Pharma, Inc. position peaked at $1.87M in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Capital International Sarl's 13F filing for Q3 2017, filed 14 Nov 2017.